Skip to content

Research at St Andrews

Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis

Research output: Contribution to journalArticle

Author(s)

Federica Fregonese, Shama D Ahuja, Onno W Akkerman, Denise Arakaki-Sanchez, Irene Ayakaka, Parvaneh Baghaei, Didi Bang, Mayara Bastos, Andrea Benedetti, Maryline Bonnet, Adithya Cattamanchi, Peter Cegielski, Jung-Yien Chien, Helen Cox, Martin Dedicoat, Connie Erkens, Patricio Escalante, Dennis Falzon, Anthony J Garcia-Prats, Medea Gegia & 38 others Stephen H Gillespie, Judith R Glynn, Stefan Goldberg, David Griffith, Karen R Jacobson, James C Johnston, Edward C Jones-López, Awal Khan, Won-Jung Koh, Afranio Kritski, Zhi Yi Lan, Jae Ho Lee, Pei Zhi Li, Ethel L Maciel, Rafael Mello Galliez, Corinne S C Merle, Melinda Munang, Gopalan Narendran, Viet Nhung Nguyen, Andrew Nunn, Akihiro Ohkado, Jong Sun Park, Patrick P J Phillips, Chinnaiyan Ponnuraja, Randall Reves, Kamila Romanowski, Kwonjune Seung, H Simon Schaaf, Alena Skrahina, Dick van Soolingen, Payam Tabarsi, Anete Trajman, Lisa Trieu, Velayutham V Banurekha, Piret Viiklepp, Jann-Yuan Wang, Takashi Yoshiyama, Dick Menzies

School/Research organisations

Abstract

Background: Isoniazid-resistant, rifampicin-susceptible (INH-R) tuberculosis is the most common form of drug resistance, and is associated with failure, relapse, and acquired rifampicin resistance if treated with first-line anti-tuberculosis drugs. The aim of the study was to compare success, mortality, and acquired rifampicin resistance in patients with INH-R pulmonary tuberculosis given different durations of rifampicin, ethambutol, and pyrazinamide (REZ); a fluoroquinolone plus 6 months or more of REZ; and streptomycin plus a core regimen of REZ.

Methods: Studies with regimens and outcomes known for individual patients with INH-R tuberculosis were eligible, irrespective of the number of patients if randomised trials, or with at least 20 participants if a cohort study. Studies were identified from two relevant systematic reviews, an updated search of one of the systematic reviews (for papers published between April 1, 2015, and Feb 10, 2016), and personal communications. Individual patient data were obtained from authors of eligible studies. The individual patient data meta-analysis was performed with propensity score matched logistic regression to estimate adjusted odds ratios (aOR) and risk differences of treatment success (cure or treatment completion), death during treatment, and acquired rifampicin resistance. Outcomes were measured across different treatment regimens to assess the effects of: different durations of REZ (≤6 months vs >6 months); addition of a fluoroquinolone to REZ (fluoroquinolone plus 6 months or more of REZ vs 6 months or more of REZ); and addition of streptomycin to REZ (streptomycin plus 6 months of rifampicin and ethambutol and 1–3 months of pyrazinamide vs 6 months or more of REZ). The overall quality of the evidence was assessed using GRADE methodology.

Findings: Individual patient data were requested for 57 cohort studies and 17 randomised trials including 8089 patients with INH-R tuberculosis. We received 33 datasets with 6424 patients, of which 3923 patients in 23 studies received regimens related to the study objectives. Compared with a daily regimen of 6 months of (H)REZ (REZ with or without isoniazid), extending the duration to 8–9 months had similar outcomes; as such, 6 months or more of (H)REZ was used for subsequent comparisons. Addition of a fluoroquinolone to 6 months or more of (H)REZ was associated with significantly greater treatment success (aOR 2·8, 95% CI 1·1–7·3), but no significant effect on mortality (aOR 0·7, 0·4–1·1) or acquired rifampicin resistance (aOR 0·1, 0·0–1·2). Compared with 6 months or more of (H)REZ, the standardised retreatment regimen (2 months of streptomycin, 3 months of pyrazinamide, and 8 months of isoniazid, rifampicin, and ethambutol) was associated with significantly worse treatment success (aOR 0·4, 0·2–0·7). The quality of the evidence was very low for all outcomes and treatment regimens assessed, owing to the observational nature of most of the data, the diverse settings, and the imprecision of estimates.

Interpretation: In patients with INH-R tuberculosis, compared with treatment with at least 6 months of daily REZ, addition of a fluoroquinolone was associated with better treatment success, whereas addition of streptomycin was associated with less treatment success; however, the quality of the evidence was very low. These results support the conduct of randomised trials to identify the optimum regimen for this important and common form of drug-resistant tuberculosis.

Funding World Health Organization and Canadian Institutes of Health Research.
Close

Details

Original languageEnglish
Pages (from-to)265-275
Number of pages11
JournalThe Lancet Respiratory Medicine
Volume6
Issue number4
Early online date23 Mar 2018
DOIs
Publication statusPublished - Apr 2018

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. Mimicking in-vivo exposures to drug combinations in-vitro: anti-tuberculosis drugs in lung lesions and the hollow fiber model of infection

    Kloprogge, F., Hammond, R., Kipper, K., Gillespie, S. H. & Della Pasqua, O., 13 Sep 2019, In : Scientific Reports. 9, 8 p., 13228.

    Research output: Contribution to journalArticle

  2. A tuberculosis molecular bacterial load assay (TB-MBLA)

    Sabiiti, W., Mtafya, B. A., Alferes De Lima, D., Dombay, E., Baron, V. O., Azam, K., Orascova, K., Sloan, D. J. & Gillespie, S. H., 6 Sep 2019, (Accepted/In press) In : Journal of Visualized Experiments.

    Research output: Contribution to journalArticle

  3. Can phenotypic data complement our understanding of antimycobacterial effects for drug combinations?

    Kloprogge, F., Hammond, R., Copas, A., Gillespie, S. H. & Della Pasqua, O., 25 Aug 2019, In : Journal of Antimicrobial Chemotherapy. Advance article, 7 p.

    Research output: Contribution to journalArticle

  4. Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status

    Tweed, C. D., Crook, A. M., Dawson, R., Diacon, A. H., McHugh, T. D., Mendel, C. M., Meredith, S. K., Mohapi, L., Murphy, M. E., Nunn, A. J., Phillips, P. P. J., Singh, K. P., Spigelman, M. & Gillespie, S. H., 14 Aug 2019, In : BMC Pulmonary Medicine. 19, 9 p., 152.

    Research output: Contribution to journalArticle

  5. Model-based relationship between the molecular bacterial load assay and time-to-positivity in liquid culture

    Svensson, R. J., Sabiiti, W., Kibiki, G. S., Ntinginya, N. E., Bhatt, N., Davies, G., Gillespie, S. H. & Simonsson, U. S. H., 29 Jul 2019, In : Antimicrobial Agents and Chemotherapy. Early

    Research output: Contribution to journalArticle

Related by journal

  1. Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment

    Friedrich, S. O., Rachow, A., Saathoff, E., Singh, K., Mangu, C. D., Dawson, R., Phillips, P., Venter, A., Bateson, A., Boehme, C. C., Heinrich, N., Hunt, R., Boeree, M. J., Zumla, A., McHugh, T. D., Gillespie, S. H., Diacon, A. & Hoelscher, M., 2013, In : The Lancet Respiratory Medicine. 1, 6, p. 462-470 9 p.

    Research output: Contribution to journalArticle

  2. Whole-genome sequencing to establish relapse or re-infection with Mycobacterium tuberculosis: a retrospective observational study

    Bryant, J. M., Harris, S. R., Parkhill, J., Dawson, R., Diacon, A., van Helden, P., Pym, A., Ahmad Mahayiddin, A., Chuchottaworn, C., Sanne, I. M., Louw, C., Boeree, M. J., Hoelscher, M., McHugh, T. D., Bateson, A. L. C., Hunt, R. D., Mwaigwisya, S., Wright, L., Gillespie, S. H. & Bentley, S. D., Dec 2013, In : The Lancet Respiratory Medicine. 1, 10, p. 786–792 6 p.

    Research output: Contribution to journalArticle

ID: 252624952